Laboratory:Hachioji

Laboratory:Hachioji
TEST NAME |
SPECIMEN REQUIREMENT (mL) |
CONTAINER | CAP COLOR | STORE TEMPERATURE (STABILITY) |
TURNAROUND TIME (DAY) |
METHODOLOGY | REFERENCE RANGE (UNIT) |
BLOOD COLLECTION TIME |
---|---|---|---|---|---|---|---|---|
|
serum
0.5 |
S7P ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
4-12 (μg/mL) |
Immediately before the next administration(Trough concentration) |
|
plasma
0.5 |
PH5 ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
4-12 (μg/mL) |
Immediately before the next administration(Trough concentration) |
Clonazepam
|
serum
0.3 |
S7P ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
20-70 (ng/mL) |
Immediately before the next administration(Trough concentration) |
Diazepam
|
serum
0.5 |
S7P ↓ A00 |
![]() |
![]() |
3-5 |
HPLC High performance liquid chromatography (HPLC) |
Diazepam 600-1000 (ng/mL) |
Immediately before the next administration(Trough concentration) However, if it is used as an ant |
|
serum
0.5 |
S7P ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
40.0-100.0 (μg/mL) |
Immediately before the next administration(Trough concentration) |
|
plasma
0.5 |
PH5 ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
40.0-100.0 (μg/mL) |
Immediately before the next administration(Trough concentration) |
Clobazam
|
serum
0.3 |
S7P ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
(ng/mL) | |
Nitrazepam
|
serum
0.3 |
S7P ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
20-200 (ng/mL) |
Immediately before the next administration(Trough concentration) However, if it is used as an ant |
|
serum
0.5 |
S7P ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
10-40 (μg/mL) |
Immediately before the next administration(Trough concentration) |
|
plasma
0.5 |
PH5 ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
10-40 (μg/mL) |
Immediately before the next administration(Trough concentration) |
|
serum
0.5 |
S7P ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
10.0-20.0 (μg/mL) |
Oral:Immediately before the next administration(Trough concentration) Intravenous:Postdose2-4 hou |
|
plasma
0.5 |
PH5 ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
10.0-20.0 (μg/mL) |
Oral:Immediately before the next administration(Trough concentration) Intravenous:Postdose2-4 hou |
|
serum
0.3 |
S7P ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
5.0-12.0 (μg/mL) |
Immediately before the next administration(Trough concentration) |
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
5.0-12.0 (μg/mL) |
Immediately before the next administration(Trough concentration) |
|
serum
0.5 |
S7P ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
50-100 (μg/mL) |
Immediately before the next administration(Trough concentration) |
|
plasma
0.5 |
PH5 ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
50-100 (μg/mL) |
Immediately before the next administration(Trough concentration) |
Trimethadione
|
serum
0.5 |
S7P ↓ A00 |
![]() |
![]() (12 days) |
7-13 | LC-MS/MS |
300-500 (μg/mL) |
|
Zonisamide
|
serum
0.5 |
S7P ↓ A00 |
![]() |
![]() |
2-4 | Latex agglutination method |
10-30 (μg/mL) |
Immediately before the next administration(Trough concentration) |
Gabapentin
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
(μg/mL) | |
Lamotrigine
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
(μg/mL) | |
Topiramate
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() (21 days) |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
(μg/mL) | |
Levetiracetam
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() (21 days) |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
12-46 (μg/mL) | Immediately before the next administration(Trough concentration) |
Stiripentol
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() (28 days) |
5-11 |
LC/MS/MS LC/MS/MS(Liquid chromatography tandem mass spectrometry) |
(μg/mL) | |
Perampanel
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() (28 days) |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
(ng/mL) | |
Rufinamide
|
plasma
0.3 |
PN2,PN5 ↓ A00 |
![]() |
![]() (28 days) |
3ー9 |
LC/MS/MS LC/MS/MS(Liquid chromatography tandem mass spectrometry) |
(μg/mL) | |
Lacosamide
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() (28 days) |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
(μg/mL) | Immediately before the next administration(Trough concentration) |
Acetazolamide
|
serum
0.3 |
S7P ↓ A00 |
![]() |
![]() |
3-9 |
HPLC High performance liquid chromatography (HPLC) |
(μg/mL) | |
|
serum
1.0 |
S7P ↓ A00 |
![]() |
![]() (14 days) |
4-10 |
Ultrafiltration EIA Enzyme immunoassay (EIA) |
1.0-2.0(μg/mL) |
Oral:Immediately before the next administration(Trough concentration) Intravenous:Postdose2-4 hou |
|
serum
1.0 |
S7P ↓ A00 |
![]() |
![]() (14 days) |
4-10 | Ultrafiltration EIA | 5.0-15.0(μg/mL) | Immediately before the next administration(Trough concentration) |